P2D, INC
Cincinnati, OH · Biotech · Acquired
Small molecule drug that inhibits latexin protein activity in hematopoietic stem cells to mitigate radiation injury
p2dinc.com →- Grants
- $6.3M
- 15 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · PancreasCHIP - A diagnostic tool for Inheritable Pancreatic Disease | $266,046 | |
| Federal grant | Department of Health and Human Services · Phase II · LIVERCHIP - A diagnostic tool for genetic liver diseases | $560,619 | |
| Federal grant | Department of Health and Human Services · Phase I · PancreasCHIP - A diagnostic tool for Inheritable Pancreatic Disease | $266,046 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment. | $745,321 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment. | $744,572 | |
| Federal grant | Department of Health and Human Services · Phase I · Activated protein C peptides for radio-mitigation | $298,750 | |
| Federal grant | Department of Health and Human Services · Phase I · Activated protein C peptides for radio-mitigation | $591,344 | |
| Federal grant | Department of Health and Human Services · Phase I · Activated protein C peptides for radio-mitigation | $292,594 | |
| Federal grant | Department of Health and Human Services · Phase II · A first-in-class orally active anti-TNF-alpha inhibitor to treat AD | $337,833 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting Latexin for radiation mitigation. | $297,014 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting Latexin for radiation mitigation. | $581,320 | |
| Federal grant | Department of Health and Human Services · Phase II · A first-in-class orally active anti-TNF-alpha inhibitor to treat AD | $166,732 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting Latexin for radiation mitigation. | $284,306 | |
| Federal grant | Department of Health and Human Services · Phase II · A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD | $470,041 | |
| Federal grant | Department of Health and Human Services · Phase II · A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD | $374,169 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3210 | Culture Robotics, Inc | — | — |
| 3211 | Venomyx, Inc. | — | — |
| 3212 | General Presence Inc. | — | $5K |
| 3213 | P2D, INC | — | — |
| 3214 | Artios Pharma | — | — |
| 3215 | HAWA THERAPEUTICS LLC | — | — |
| 3216 | Poplar Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Substituted Benztropine Analogs For Treatment Of Dementiaapplication
- Substituted Benztropine Analogs For Treatment Of Dementiaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.